234 related articles for article (PubMed ID: 22343223)
1. The novel NF-κB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism.
Lampiasi N; Azzolina A; Umezawa K; Montalto G; McCubrey JA; Cervello M
Cancer Lett; 2012 Sep; 322(1):35-44. PubMed ID: 22343223
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism.
Lampiasi N; Azzolina A; D'Alessandro N; Umezawa K; McCubrey JA; Montalto G; Cervello M
Mol Pharmacol; 2009 Aug; 76(2):290-300. PubMed ID: 19461054
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effects of the novel NF-kappaB inhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer cells: analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production.
Poma P; Notarbartolo M; Labbozzetta M; Sanguedolce R; Alaimo A; Carina V; Maurici A; Cusimano A; Cervello M; D'Alessandro N
Int J Oncol; 2006 Apr; 28(4):923-30. PubMed ID: 16525642
[TBL] [Abstract][Full Text] [Related]
4. DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells.
Nishimura D; Ishikawa H; Matsumoto K; Shibata H; Motoyoshi Y; Fukuta M; Kawashimo H; Goto T; Taura N; Ichikawa T; Hamasaki K; Nakao K; Umezawa K; Eguchi K
Int J Oncol; 2006 Sep; 29(3):713-9. PubMed ID: 16865289
[TBL] [Abstract][Full Text] [Related]
5. Effects of a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines.
Ruan HY; Masuda M; Ito A; Umezawa K; Nakashima T; Yasumatsu R; Kuratomi Y; Yamamoto T; Weinstein IB; Komune S
Head Neck; 2006 Feb; 28(2):158-65. PubMed ID: 16355386
[TBL] [Abstract][Full Text] [Related]
6. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.
Matsumoto G; Namekawa J; Muta M; Nakamura T; Bando H; Tohyama K; Toi M; Umezawa K
Clin Cancer Res; 2005 Feb; 11(3):1287-93. PubMed ID: 15709200
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of nuclear factor-κB by dehydroxymethylepoxyquinomicin induces schedule-dependent chemosensitivity to anticancer drugs and enhances chemoinduced apoptosis in osteosarcoma cells.
Castro-Gamero AM; Borges KS; da Silva Silveira V; Lira RC; de Paula Gomes Queiroz R; Valera FC; Scrideli CA; Umezawa K; Tone LG
Anticancer Drugs; 2012 Jul; 23(6):638-50. PubMed ID: 22382389
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effect of a novel nuclear factor-kappa B activation inhibitor in bladder cancer cells.
Horiguchi Y; Kuroda K; Nakashima J; Murai M; Umezawa K
Expert Rev Anticancer Ther; 2003 Dec; 3(6):793-8. PubMed ID: 14686701
[TBL] [Abstract][Full Text] [Related]
9. Targeting NF-kappaB and induction of apoptosis by novel NF-kappaB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells.
Kimura N; Miyakawa Y; Kohmura K; Umezawa K; Ikeda Y; Kizaki M
Leuk Res; 2007 Nov; 31(11):1529-35. PubMed ID: 17466373
[TBL] [Abstract][Full Text] [Related]
10. Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin.
Starenki DV; Namba H; Saenko VA; Ohtsuru A; Maeda S; Umezawa K; Yamashita S
Clin Cancer Res; 2004 Oct; 10(20):6821-9. PubMed ID: 15501958
[TBL] [Abstract][Full Text] [Related]
11. AEE788 potentiates celecoxib-induced growth inhibition and apoptosis in human colon cancer cells.
Venkatesan P; Bhutia SK; Singh AK; Das SK; Dash R; Chaudhury K; Sarkar D; Fisher PB; Mandal M
Life Sci; 2012 Oct; 91(15-16):789-99. PubMed ID: 22922496
[TBL] [Abstract][Full Text] [Related]
12. The NF-κB inhibitor DHMEQ decreases survival factors, overcomes the protective activity of microenvironment and synergizes with chemotherapy agents in classical Hodgkin lymphoma.
Celegato M; Borghese C; Umezawa K; Casagrande N; Colombatti A; Carbone A; Aldinucci D
Cancer Lett; 2014 Jul; 349(1):26-34. PubMed ID: 24704296
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor activity of dehydroxymethylepoxyquinomicin against human oral squamous cell carcinoma cell lines in vitro and in vivo.
Yasuda A; Kondo S; Nagumo T; Tsukamoto H; Mukudai Y; Umezawa K; Shintani S
Oral Oncol; 2011 May; 47(5):334-9. PubMed ID: 21459660
[TBL] [Abstract][Full Text] [Related]
14. Growth suppression and apoptosis induction in synovial sarcoma cell lines by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ).
Horiuchi K; Morioka H; Nishimoto K; Suzuki Y; Susa M; Nakayama R; Kawai A; Sonobe H; Takaishi H; Ozaki T; Yabe H; Umezawa K; Toyama Y
Cancer Lett; 2008 Dec; 272(2):336-44. PubMed ID: 18760530
[TBL] [Abstract][Full Text] [Related]
15. Parthenolide cooperates with NS398 to inhibit growth of human hepatocellular carcinoma cells through effects on apoptosis and G0-G1 cell cycle arrest.
Ralstin MC; Gage EA; Yip-Schneider MT; Klein PJ; Wiebke EA; Schmidt CM
Mol Cancer Res; 2006 Jun; 4(6):387-99. PubMed ID: 16778086
[TBL] [Abstract][Full Text] [Related]
16. A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo.
Watanabe M; Dewan MZ; Okamura T; Sasaki M; Itoh K; Higashihara M; Mizoguchi H; Honda M; Sata T; Watanabe T; Yamamoto N; Umezawa K; Horie R
Int J Cancer; 2005 Mar; 114(1):32-8. PubMed ID: 15523684
[TBL] [Abstract][Full Text] [Related]
17. Pleiotropic potential of dehydroxymethylepoxyquinomicin for NF-κB suppression via reactive oxygen species and unfolded protein response.
Nakajima S; Kato H; Gu L; Takahashi S; Johno H; Umezawa K; Kitamura M
J Immunol; 2013 Jun; 190(12):6559-69. PubMed ID: 23690471
[TBL] [Abstract][Full Text] [Related]
18. Survivin associates with cell proliferation in renal cancer cells: regulation of survivin expression by insulin-like growth factor-1, interferon-gamma and a novel NF-kappaB inhibitor.
Sato A; Oya M; Ito K; Mizuno R; Horiguchi Y; Umezawa K; Hayakawa M; Murai M
Int J Oncol; 2006 Apr; 28(4):841-6. PubMed ID: 16525632
[TBL] [Abstract][Full Text] [Related]
19. Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent.
Katsman A; Umezawa K; Bonavida B
Drug Resist Updat; 2007; 10(1-2):1-12. PubMed ID: 17306602
[TBL] [Abstract][Full Text] [Related]
20. A small molecule inhibitor of NF-kappaB, dehydroxymethylepoxyquinomicin (DHMEQ), suppresses growth and invasion of nasopharyngeal carcinoma (NPC) cells.
Wong JH; Lui VW; Umezawa K; Ho Y; Wong EY; Ng MH; Cheng SH; Tsang CM; Tsao SW; Chan AT
Cancer Lett; 2010 Jan; 287(1):23-32. PubMed ID: 19560263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
